⌕
Biocryst Pharmaceuticals · BCRX · Nasdaq
Tenet 73 · Solid
Compare
$7.45−2.10%At closeTenet 73 · Solid
$7.45−0.16 (−2.10%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

Biocryst Pharmaceuticals (BCRX) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice
Business engineGrowing fast: revenue compounds ~53.6%/yr (FY21→FY25), net margin 30.2%, and free cash flow (~$344.9M) tracks net income. Earnings are cash, not paper. Worth your attention in FY25: Share count (+22.0%) and Capex step-up ($2.5M). Both visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▲94.1%
874.8
FY21→FY25CAGR +53.6%/yr
Net income ($M)—
263.9
FY21→FY25CAGR —
Free cash flow ($M)—
344.9
capex stepped upCAGR —
Diluted EPS—
1.21
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+22.0%

179.1mn → 218.6mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.

Capex step-up
$2.5M

▲120% YoY in FY25, largest jump in this window; watch free-cash-flow conversion.

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)874.8Revenue−19.1COGS855.8Gross profit−166.1R&D−348.6SG&A341.0Op income−77.1Tax & other263.9Net income

30¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.

Margin trend · direction beats level Gross Operating Net
1007550250%sector median net margin ~4%FY21FY25

Over this window: gross 95.4% → 97.8%. Net margin 30.2% is more than double the sector median.

The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
Line itemTTM †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
961,510.0874,837.0450,712.0331,412.0270,827.0157,170.0▲94.1%+53.6%
Cost of revenue
20,313.019,075.012,269.04,481.06,408.07,229.0▲55.5%+27.5%
Gross profit
941,197.0855,762.0438,443.0326,931.0264,419.0149,941.0▲95.2%+54.6%
Research & development
909,129.0166,126.0174,638.0216,566.0253,297.0208,808.0▼4.9%−5.6%
Selling, general & admin
321,486.0348,647.0266,348.0214,074.0159,371.0118,818.0▲30.9%+30.9%
Total operating expenses
1,230,615.0514,773.0440,986.0430,640.0412,854.0327,661.0▲16.7%+12.0%
Operating incomefeeds ROC rank
−289,418.0340,989.0−2,543.0−103,709.0−148,435.0−177,720.0——
Other income, net
−65,314.0−73,598.0−84,411.0−122,520.0−95,948.0−4,089.0——
Pretax income
−354,732.0267,391.0−86,954.0−226,229.0−244,383.0−181,809.0——
Income tax
4,924.03,530.01,927.0310.02,733.02,253.0▲83.2%+11.9%
Net incomePiotroski ROA ✓feeds Buffett Quality owner earnings
−359,656.0263,861.0−88,881.0−226,539.0−247,116.0−184,062.0——
Per share
Diluted EPSbuyback-sensitive
−1.411.21−0.43−1.18−1.33−1.03——
Diluted shares (mn)
267.62218.58206.70192.20185.91179.12▲5.7%+5.1%
Margins
Gross margin95th pct in Healthcare
97.9%97.8%97.3%98.6%97.6%95.4%▲0.5pp+2.4pp
Operating margin
−30.1%39.0%−0.6%−31.3%−54.8%−113.1%▲39.5pp+152.1pp
Net margin17th pct in Healthcare
−37.4%30.2%−19.7%−68.4%−91.2%−117.1%▲49.9pp+147.3pp
† TTM = trailing four quarters through 2026-09-30.
FY09 – FY20 · 12 more years
Unlock the full history →
5 more years of statements and CSV export are on Premium, and 12 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-02-26 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.

What was Biocryst Pharmaceuticals' revenue last fiscal year?

Biocryst Pharmaceuticals reported revenue of $874.8M in fiscal 2025, up 94.1% from fiscal 2024.

What was Biocryst Pharmaceuticals' net income?

Biocryst Pharmaceuticals reported net income of $263.9M in fiscal 2025, a net margin of 30.2%.

Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.